Literature DB >> 27646470

Understanding how long-acting β2 -adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids in asthma - an update.

Robert Newton1, Mark A Giembycz2.   

Abstract

In moderate-to-severe asthma, adding an inhaled long-acting β2 -adenoceptor agonist (LABA) to an inhaled corticosteroid (ICS) provides better disease control than simply increasing the dose of ICS. Acting on the glucocorticoid receptor (GR, gene NR3C1), ICSs promote anti-inflammatory/anti-asthma gene expression. In vitro, LABAs synergistically enhance the maximal expression of many glucocorticoid-induced genes. Other genes, including dual-specificity phosphatase 1(DUSP1) in human airways smooth muscle (ASM) and epithelial cells, are up-regulated additively by both drug classes. Synergy may also occur for LABA-induced genes, as illustrated by the bronchoprotective gene, regulator of G-protein signalling 2 (RGS2) in ASM. Such effects cannot be produced by either drug alone and may explain the therapeutic efficacy of ICS/LABA combination therapies. While the molecular basis of synergy remains unclear, mechanistic interpretations must accommodate gene-specific regulation. We explore the concept that each glucocorticoid-induced gene is an independent signal transducer optimally activated by a specific, ligand-directed, GR conformation. In addition to explaining partial agonism, this realization provides opportunities to identify novel GR ligands that exhibit gene expression bias. Translating this into improved therapeutic ratios requires consideration of GR density in target tissues and further understanding of gene function. Similarly, the ability of a LABA to interact with a glucocorticoid may be suboptimal due to low β2 -adrenoceptor density or biased β2 -adrenoceptor signalling. Strategies to overcome these limitations include adding-on a phosphodiesterase inhibitor and using agonists of other Gs-coupled receptors. In all cases, the rational design of ICS/LABA, and derivative, combination therapies requires functional knowledge of induced (and repressed) genes for therapeutic benefit to be maximized.
© 2016 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27646470      PMCID: PMC5120156          DOI: 10.1111/bph.13628

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  279 in total

Review 1.  Molecular mechanisms of glucocorticoid action: what is important?

Authors:  R Newton
Journal:  Thorax       Date:  2000-07       Impact factor: 9.139

2.  Opposing effects of corepressor and coactivators in determining the dose-response curve of agonists, and residual agonist activity of antagonists, for glucocorticoid receptor-regulated gene expression.

Authors:  D Szapary; Y Huang; S S Simons
Journal:  Mol Endocrinol       Date:  1999-12

3.  Up-regulation of airway smooth muscle histamine H(1) receptor mRNA, protein, and function by beta(2)-adrenoceptor activation.

Authors:  J C Mak; A F Roffel; T Katsunuma; C R Elzinga; J Zaagsma; P J Barnes
Journal:  Mol Pharmacol       Date:  2000-05       Impact factor: 4.436

4.  Synergistic inhibition by beta(2)-agonists and corticosteroids on tumor necrosis factor-alpha-induced interleukin-8 release from cultured human airway smooth-muscle cells.

Authors:  L Pang; A J Knox
Journal:  Am J Respir Cell Mol Biol       Date:  2000-07       Impact factor: 6.914

5.  Glucocorticoids inhibit proliferation, cyclin D1 expression, and retinoblastoma protein phosphorylation, but not activity of the extracellular-regulated kinases in human cultured airway smooth muscle.

Authors:  D Fernandes; E Guida; V Koutsoubos; T Harris; P Vadiveloo; J W Wilson; A G Stewart
Journal:  Am J Respir Cell Mol Biol       Date:  1999-07       Impact factor: 6.914

6.  Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12.

Authors:  K Ito; P J Barnes; I M Adcock
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

7.  p57Kip2, a glucocorticoid-induced inhibitor of cell cycle progression in HeLa cells.

Authors:  M K Samuelsson; A Pazirandeh; B Davani; S Okret
Journal:  Mol Endocrinol       Date:  1999-11

8.  Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA).

Authors:  S Shrewsbury; S Pyke; M Britton
Journal:  BMJ       Date:  2000-05-20

9.  Phosphorylation of caldesmon by ERK MAP kinases in smooth muscle.

Authors:  J C Hedges; B C Oxhorn; M Carty; L P Adam; I A Yamboliev; W T Gerthoffer
Journal:  Am J Physiol Cell Physiol       Date:  2000-04       Impact factor: 4.249

10.  beta(2)-adrenoceptor agonist-induced upregulation of tachykinin NK(2) receptor expression and function in airway smooth muscle.

Authors:  T Katsunuma; A F Roffel; C R Elzinga; J Zaagsma; P J Barnes; J C Mak
Journal:  Am J Respir Cell Mol Biol       Date:  1999-09       Impact factor: 6.914

View more
  15 in total

Review 1.  Activation of β2 adrenergic receptor signaling modulates inflammation: a target limiting the progression of kidney diseases.

Authors:  Debra Dorotea; Hunjoo Ha
Journal:  Arch Pharm Res       Date:  2020-11-05       Impact factor: 4.946

2.  Protective Roles for RGS2 in a Mouse Model of House Dust Mite-Induced Airway Inflammation.

Authors:  Tresa George; Matthew Bell; Mainak Chakraborty; David P Siderovski; Mark A Giembycz; Robert Newton
Journal:  PLoS One       Date:  2017-01-20       Impact factor: 3.240

Review 3.  Role and regulation of MKP-1 in airway inflammation.

Authors:  Seyed M Moosavi; Pavan Prabhala; Alaina J Ammit
Journal:  Respir Res       Date:  2017-08-10

4.  Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways.

Authors:  Luigino Calzetta; Maria Gabriella Matera; Francesco Facciolo; Mario Cazzola; Paola Rogliani
Journal:  Respir Res       Date:  2018-04-12

5.  Glucocorticoid-driven transcriptomes in human airway epithelial cells: commonalities, differences and functional insight from cell lines and primary cells.

Authors:  Mahmoud M Mostafa; Christopher F Rider; Suharsh Shah; Suzanne L Traves; Paul M K Gordon; Anna Miller-Larsson; Richard Leigh; Robert Newton
Journal:  BMC Med Genomics       Date:  2019-01-31       Impact factor: 3.063

6.  Comparative Transcriptomic Analysis Reveals Diverse Expression Pattern Underlying Fatty Acid Composition among Different Beef Cuts.

Authors:  Tianliu Zhang; Qunhao Niu; Tianzhen Wang; Xu Zheng; Haipeng Li; Xue Gao; Yan Chen; Huijiang Gao; Lupei Zhang; George E Liu; Junya Li; Lingyang Xu
Journal:  Foods       Date:  2022-01-04

7.  A bronchoprotective role for Rgs2 in a murine model of lipopolysaccharide-induced airways inflammation.

Authors:  Tresa George; Mainak Chakraborty; Mark A Giembycz; Robert Newton
Journal:  Allergy Asthma Clin Immunol       Date:  2018-10-01       Impact factor: 3.406

8.  Glucocorticoids rapidly activate cAMP production via Gαs to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.

Authors:  Francisco J Nuñez; Timothy B Johnstone; Maia L Corpuz; Austin G Kazarian; Nicole N Mohajer; Omar Tliba; Reynold A Panettieri; Cynthia Koziol-White; Moom R Roosan; Rennolds S Ostrom
Journal:  FASEB J       Date:  2019-12-27       Impact factor: 5.191

9.  The rescue intervention strategy for asthma patients under severe air pollution: a protocol for a single-centre prospective randomized controlled trial.

Authors:  Xiaoyu Yang; Junjun Huang; Yan Hu; Cuiyan Guo; Xi Wang; Zhao Yang; Tianyu Zhou; Guangfa Wang
Journal:  Trials       Date:  2020-11-04       Impact factor: 2.279

Review 10.  Packaging and Delivery of Asthma Therapeutics.

Authors:  Bryan J Mathis; Misa Kusumoto; Alexander Zaboronok; Yuji Hiramatsu
Journal:  Pharmaceutics       Date:  2021-12-31       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.